Patricia Beaston
Sernova Biotherapeutics Inc.Dr. Patricia Beaston, MD, PhD, is Chief Medical Officer of Seraxis Holdings, Inc. and Sernova Biotherapeutics Inc. from October 2026. Dr. Beaston strengthens Seraxis' clinical and regulatory leadership as it prepares to initiate the Phase 1/2 clinical trial of SR-02, pancreatic stem cell-derived insulin producing islets, with first patient dosing targeted. During her FDA tenure, Dr. Beaston served across three of the agency's principal centers. At the Center for Drug Evaluation and Research (CDER), she evaluated endocrine therapeutics and subsequently joined the Center for Devices and Radiological Health (CDRH). Most recently, at the Center for Biologics Evaluation and Research (CBER), her review responsibilities included islet cell transplantation, immune modulation in T1D, cell and gene therapies and xenotransplantation. Dr. Beaston earned her PhD in Anatomy and Neurobiology and MD from the Medical College of Pennsylvania, following a BS in Zoology from the University of Maryland. She completed her residency in Internal Medicine at the Medical College of Pennsylvania and a fellowship in Diabetes, Endocrinology and Metabolism at Penn State/Hershey.
Positions
- Company NameSernova Biotherapeutics IncStock CodeSEOVFPositionSernova Biotherapeutics Inc.Colleagues
- JMJonathan M. N. RigbyPresident, CEO & Director
- JLJohn L. BrooksIndependent Chairman
- JTJames T. ParsonsChief Financial Officer
- MRMarylyn RigbyChief Communications Officer
- DBDavid BurkeVice President of Investor Relations
- RARobert A. GabbayChairman of Clinical Advisory Board
- NCNorman C. W. WongMember of Scientific Advisory Board
- JDJannette DufourMember of Scientific Advisory Board
